OBJECTIVES: A gluten-free diet is the treatment for celiac disease, but pharmaceutical agents are being developed. The level of interest amongst patients in using a medication to treat celiac disease is unknown. This study examined the level of interest amongst patients in medication to treat celiac disease. METHODS: A questionnaire was distributed to celiac disease patients and data were collected on demographics, presentation, and interest in medication. Three validated celiac disease-specific instruments were incorporated: Celiac Disease Associated Quality of Life, the Celiac Symptom Index, and the Celiac Dietary Adherence Test. RESULTS: Responses were received from 365 individuals with biopsy-proven celiac disease. Respondents were 78% (n = 276) female, 48% (n = 170) over 50 years of age, and experienced a classical (diarrhea predominant) presentation in 44% (n = 154). Of the 339 individuals answering the question regarding use of a medication to treat celiac disease, 66% were interested. Interest was greatest in older individuals (71% >50 years of age versus 60% <50 years of age, p = 0.0415), men (78% men versus 62% women, p = 0.0083), frequent restaurant customers (76% versus 58%, p = 0.0006), those dissatisfied with their weight (73% versus 51%, p = 0.0003) and those concerned with the cost of a gluten-free diet (77% versus 64%, p = 0.0176). Length of time since diagnosis, education, presentation, and symptoms with gluten exposure did not demonstrate any effect. Interest in medication was associated with a worse quality of life (CD-QOL 69.4 versus 80.1, p < 0.0001). CONCLUSIONS: Most individuals with celiac disease are interested in using a medication. Interest was highest among men, older individuals, frequent restaurant customers, individuals dissatisfied with their weight or concerned with the cost of a gluten-free diet, and those with a worse quality of life.
OBJECTIVES: A gluten-free diet is the treatment for celiac disease, but pharmaceutical agents are being developed. The level of interest amongst patients in using a medication to treat celiac disease is unknown. This study examined the level of interest amongst patients in medication to treat celiac disease. METHODS: A questionnaire was distributed to celiac disease patients and data were collected on demographics, presentation, and interest in medication. Three validated celiac disease-specific instruments were incorporated: Celiac Disease Associated Quality of Life, the Celiac Symptom Index, and the Celiac Dietary Adherence Test. RESULTS: Responses were received from 365 individuals with biopsy-proven celiac disease. Respondents were 78% (n = 276) female, 48% (n = 170) over 50 years of age, and experienced a classical (diarrhea predominant) presentation in 44% (n = 154). Of the 339 individuals answering the question regarding use of a medication to treat celiac disease, 66% were interested. Interest was greatest in older individuals (71% >50 years of age versus 60% <50 years of age, p = 0.0415), men (78% men versus 62% women, p = 0.0083), frequent restaurant customers (76% versus 58%, p = 0.0006), those dissatisfied with their weight (73% versus 51%, p = 0.0003) and those concerned with the cost of a gluten-free diet (77% versus 64%, p = 0.0176). Length of time since diagnosis, education, presentation, and symptoms with gluten exposure did not demonstrate any effect. Interest in medication was associated with a worse quality of life (CD-QOL 69.4 versus 80.1, p < 0.0001). CONCLUSIONS: Most individuals with celiac disease are interested in using a medication. Interest was highest among men, older individuals, frequent restaurant customers, individuals dissatisfied with their weight or concerned with the cost of a gluten-free diet, and those with a worse quality of life.
Authors: Daniel A Leffler; Jessica Edwards-George; Melinda Dennis; Detlef Schuppan; Francis Cook; Debra L Franko; Jessica Blom-Hoffman; Ciaran P Kelly Journal: Dig Dis Sci Date: 2008-06 Impact factor: 3.199
Authors: S D Dorn; L Hernandez; M T Minaya; C B Morris; Y Hu; J Leserman; S Lewis; A Lee; S I Bangdiwala; P H R Green; D A Drossman Journal: Aliment Pharmacol Ther Date: 2009-12-15 Impact factor: 8.171
Authors: Daniel A Leffler; Melinda Dennis; Jessica Edwards George; Shailaja Jamma; E Francis Cook; Detlef Schuppan; Ciaran P Kelly Journal: Clin Gastroenterol Hepatol Date: 2009-08-07 Impact factor: 11.382
Authors: C P Kelly; P H R Green; J A Murray; A Dimarino; A Colatrella; D A Leffler; T Alexander; R Arsenescu; F Leon; J G Jiang; L A Arterburn; B M Paterson; R N Fedorak Journal: Aliment Pharmacol Ther Date: 2012-11-19 Impact factor: 8.171
Authors: Henry J McSorley; Soraya Gaze; James Daveson; Dianne Jones; Robert P Anderson; Andrew Clouston; Nathalie E Ruyssers; Richard Speare; James S McCarthy; Christian R Engwerda; John Croese; Alex Loukas Journal: PLoS One Date: 2011-09-16 Impact factor: 3.240
Authors: Maria Ines Pinto-Sanchez; Elena F Verdu; Maria C Gordillo; Julio C Bai; Stephen Birch; Paul Moayyedi; Premysl Bercik Journal: Can J Gastroenterol Hepatol Date: 2015-03